Cargando…

Multiple sclerosis treatment blunts SARS-CoV-2 antibody response

Detalles Bibliográficos
Autor principal:	Lemprière, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350924/ https://www.ncbi.nlm.nih.gov/pubmed/34373633 http://dx.doi.org/10.1038/s41582-021-00551-3

Ejemplares similares

SARS-CoV-2 detected in olfactory neurons
por: Lemprière, Sarah
Publicado: (2021)

SARS-CoV-2 and the brain to be studied long-term
por: Lemprière, Sarah
Publicado: (2020)

Antibody responses to SARS-CoV-2 short-lived
por: Vabret, Nicolas
Publicado: (2020)

Publisher Correction: SARS-CoV-2 and the brain to be studied long-term
por: Lemprière, Sarah
Publicado: (2020)

Antibody response to SARS-CoV-2 — sustained after all?
por: Compeer, Ewoud B., et al.
Publicado: (2020)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

SARS-CoV-2 antibody seroconversion in care home
por: Shang, Joan, et al.
Publicado: (2020)

SARS-CoV-2-specific T cells without antibodies
por: Bozkus, Cansu Cimen
Publicado: (2020)

Human antibodies can neutralize SARS-CoV-2
por: Catalan-Dibene, Jovani
Publicado: (2020)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD
por: Ray, Katrina
Publicado: (2021)

Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis
por: Rose, Deja R, et al.
Publicado: (2021)

Outliers Matter—Correlation between S1 IgG SARS-CoV-2 Antibodies and Neutralizing SARS-CoV-2 Antibodies
por: Hocher, Berthold, et al.
Publicado: (2022)

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
por: Gyang, Tirisham V., et al.
Publicado: (2022)

SARS-CoV-2 variant evades antibodies whilst maintaining fitness
por: Flemming, Alexandra
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
por: Dashdorj, Naranjargal J., et al.
Publicado: (2021)

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
por: Bakasis, Athanasios-Dimitrios, et al.
Publicado: (2022)

Antibody Responses One Year after Mild SARS-CoV-2 Infection
por: Choe, Pyoeng Gyun, et al.
Publicado: (2021)

The Comparative Superiority of SARS-CoV-2 Antibody Response in Different Immunization Scenarios
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

Bayesian estimation of the seroprevalence of antibodies to SARS-CoV-2
por: Dong, Qunfeng, et al.
Publicado: (2020)

HCQ use not protective against SARS-CoV-2
por: Onuora, Sarah
Publicado: (2020)

SARS-CoV-2 vaccine safe for young patients
por: Onuora, Sarah
Publicado: (2022)

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis
por: Sharma, Pragya, et al.
Publicado: (2022)

Harmonization of Determination of SARS-CoV-2 Antibodies: Is It Always Possible?
por: Dittadi, Ruggero
Publicado: (2022)

Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients
por: Mallucci, Giulia, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
por: Capasso, Nicola, et al.
Publicado: (2020)

Prevalence of SARS-CoV-2 antibodies in multiple sclerosis: The hidden part of the iceberg
por: Capasso, Nicola, et al.
Publicado: (2021)

SARS-CoV-2 on the neural battleground
por: Pavillet, Clara Eléonore, et al.
Publicado: (2020)

SARS-CoV-2 likes it cool
por: Soares-Schanoski, Alessandra
Publicado: (2020)

Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020)

Clotting and SARS-CoV-2 entry
por: Hofer, Ursula
Publicado: (2022)

Histone mimicry by SARS-CoV-2
por: York, Ashley
Publicado: (2022)

SARS-CoV-2 in penile tissue
por: Thomas, Tim
Publicado: (2022)

Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx
por: Sydney, Elana R., et al.
Publicado: (2020)

In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
por: Hu, Ye-Fan, et al.
Publicado: (2022)

Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis
por: Schraad, Muriel, et al.
Publicado: (2022)

Third COVID-19 jab benefits people with MS
por: Lemprière, Sarah
Publicado: (2022)

High rate of epilepsy in young individuals who died with COVID-19
por: Lempriere, Sarah
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pnm6u22bhcmvi61gmn6frrafal